Merrill reiterates Myriad at buy

Myriad Genetics Inc. was reiterated by Merrill Lynch analyst David Munno at a buy as the company's fourth-quarter predictive medicine revenues of $28.8 million beat Merrill's estimate of $28.4 million and was in line with consensus. Enrollment of the company's phase 3 trial for Flurizan in Alzheimer's is complete, with data expected in the fourth-quarter 2007. Myriad has made progress on its predictive medicine tests for diabetes, prostate cancer and depression. Shares of the Salt Lake City-based biopharmaceutical company were down $1.56, or 5.90%, at $24.90, on volume of 745,852 shares versus the three-month running average of 316,369 shares. (Nasdaq: MYGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.